Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.17 Insider Own23.80% Shs Outstand12.21M Perf Week-22.19%
Market Cap3.33M Forward P/E- EPS next Y-0.23 Insider Trans8.43% Shs Float9.30M Perf Month28.16%
Income-0.80M PEG- EPS next Q-0.23 Inst Own3.98% Short Float2.48% Perf Quarter14.99%
Sales0.38M P/S8.78 EPS this Y62.07% Inst Trans- Short Ratio0.47 Perf Half Y-59.30%
Book/sh-0.23 P/B- EPS next Y58.18% ROA-8.53% Short Interest0.23M Perf Year-
Cash/sh0.24 P/C1.15 EPS next 5Y- ROE- 52W Range0.20 - 8.65 Perf YTD-73.23%
Dividend Est.- P/FCF- EPS past 5Y- ROI-10.89% 52W High-96.84% Beta-
Dividend TTM- Quick Ratio6.77 Sales past 5Y2.28% Gross Margin-23.44% 52W Low35.80% ATR (14)0.04
Dividend Ex-Date- Current Ratio7.16 EPS Y/Y TTM- Oper. Margin-1463.65% RSI (14)46.40 Volatility15.47% 14.43%
Employees3 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin-211.57% Recom2.00 Target Price1.30
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q109.50% Payout- Rel Volume0.47 Prev Close0.28
Sales Surprise685.87% EPS Surprise115.79% Sales Q/Q580.65% EarningsMay 15 BMO Avg Volume493.92K Price0.27
SMA20-6.89% SMA504.05% SMA200-51.54% Trades Volume234,042 Change-3.09%
Jun-11-24 07:59AM
Jun-06-24 07:38AM
May-30-24 07:59AM
May-20-24 07:59AM
May-15-24 09:55PM
01:45PM Loading…
May-08-24 07:59AM
May-02-24 07:59AM
Apr-03-24 07:58AM
Mar-14-24 07:59AM
Feb-20-24 07:59AM
Feb-08-24 07:59AM
Jan-31-24 12:00PM
Jan-30-24 09:45AM
09:00AM Loading…
Jan-22-24 07:59AM
Jan-16-24 07:59AM
Dec-26-23 07:59AM
Nov-15-23 07:29AM
Oct-19-23 08:31AM
Oct-12-23 04:16PM
Sep-18-23 04:16PM
Sep-06-23 07:31AM
Sep-01-23 09:00AM
Aug-30-23 07:32AM
Aug-22-23 07:31AM
Aug-15-23 07:31AM
Jul-31-23 07:59AM
Jul-21-23 09:00AM
01:30PM Loading…
Jul-14-23 01:30PM
Jul-12-23 01:45PM
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOW GEOFFREY SPresident and CEOMay 16 '24Option Exercise0.2217,0003,791762,625May 21 08:19 PM
Allen Charles WDirectorMay 16 '24Option Exercise0.224,00089214,000May 21 08:18 PM
FIELD PAULDirectorMay 16 '24Option Exercise0.224,00089214,000May 21 08:20 PM
XU CHERYLDirectorMay 16 '24Option Exercise0.222,000446228,934May 21 08:23 PM
DOW GEOFFREY SPresident and CEOApr 12 '24Option Exercise0.2768,00018,142745,625May 21 08:19 PM
XU CHERYLDirectorJan 31 '24Buy0.38200,00075,000424,934Feb 02 03:31 PM
DOW GEOFFREY SPresident and CEOJan 31 '24Buy0.3825,9749,740703,599Feb 02 03:33 PM